2024

Annual report

Department of Medicine
and Life Sciences

Leading innovation in life sciences

A year of breakthroughs and leadership in the UPF

The Department of Medicine and Life Sciences continues to consolidate its reputation as a leader in research. With an outstanding academic record, UPF continues to rank among the world’s top universities, while its research groups position the department at the forefront of scientific innovation.

Achievements in 2024

Projects that move science forward

Integra Therapeutics, a UPF spinoff, to receive up to €10.5 million from the European Commission to drive the FiCAT advanced therapies platform

The biotech company was chosen by the European Innovation Council (EIC) Accelerator program from among 969 European deep tech companies.
This funding will enable Integra Therapeutics to launch its first gene therapy to treat a serious pediatric hepatic disease, among other activities.

Key milestones of 2024

Dedicated to advancing education and academic excellence

0

Research projects

0

Publications

0M

€ in funding

0

Students

Key milestones of 2024

Dedicated to advancing education and academic excellence

0
0
0M

Research projects

Publications

€ in funding

0

Students

Behind the scenes

Our daily activities

Driving progress in biology and biomedicine
Driving progress in biology and biomedicine
How we shape tomorrow’s scientific minds
How we shape tomorrow’s scientific minds
Turning breakthroughs into conversations
Turning breakthroughs into conversations

Creating opportunities, changing futures

UPF MELIS Future Scholarships

Your support for the UPF MELIS Future Scholarships helps turn ambition into achievement. It’s a meaningful gesture that opens doors, empowers talent, and contributes to a more inclusive and enlightened society.

Thank you for being part of the change!